A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
Clinical trial NCT04672395 · COMPLETED
Trial details
- NCT number
- NCT04672395
- Sponsor
- Clover Biopharmaceuticals AUS Pty
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-24
- Primary completion
- 2022-09-15
- Enrollment
- 31454
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.